ClinicalTrials.gg
CompletedNCT00478608Updated Apr 28, 2010Results posted

Study Evaluating Rapamune® Maintenance Regimen

A Phase 3 interventional study of Sirolimus (Rapamune®) in Renal Transplant, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 9 sites in Korea, Republic of. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2010-04-28.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
79
Allocation
Non-randomized
Ages
13 Years and older
Sex
All
01

Study summary

Primary : To evaluate the efficacy of sirolimus assessed by the incidence of biopsy-confirmed acute rejection episode at 6 months after transplantation in Korean renal transplantation recipients.

Secondary :

  1. To evaluate the safety of sirolimus over 12 months after transplantation in Korean renal transplantation recipients.
  2. To evaluate graft function, patient survival and graft survival at 6 and 12 months after transplantation, and to investigate the incidence of biopsy-confirmed acute rejection episode at 12 months after transplantation.
02

Conditions studied

  • Renal Transplant
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age greater than or equal to 13 years of age.
  2. End-stage renal disease in patients scheduled to receive a primary renal allograft from a cadaveric donor, a living-unrelated donor, or from a living-related (excluding 0 antigen mismatch) donor. A mismatch donor is defined as a donor human leukocyte antigen (HLA) antigen not shared by the patient.
  3. Patients with a panel of reactive antibody (%PRA) less than or equal to 50%

Exclusion criteria

Exclusion Criteria:

  1. Evidence of active systemic or localized major infection at the time of initial sirolimus administration.
  2. Evidence of infiltrate, cavitation, or consolidation on chest x-ray obtained during pre-study screening.
  3. Chronic anti-arrhythmic therapy for ventricular arrhythmia or other cardiac abnormality contraindicating general anesthesia or surgery.
  4. History of within 5 years before enrollment into the study (with the exception of adequately treated basal cell or squamous cell carcinoma of the skin).
  5. Current treatment with partial opioid agonists (eg, buprenorphine) or combination agonists/antagonists.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
79 participants (actual)

Interventions

  • (1mg tablets): Initial loading dose of 6mg/day, followed by maintenance dose of 2mg/day, which was adjusted to specified trough level.

06

What researchers measure

Primary outcomes

  1. Number of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 6 After Transplantation.

    The diagnosis of acute rejection required a kidney biopsy. Biopsies were assessed using the Banff criteria, standardized diagnostic categories based on histological assessments (e.g., cell types and distributions).

    Time frame: 6 months after transplantation

Secondary outcomes

  1. Glomerular Filtration Rate (GFR) (Nankivell Method)

    GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. For this study, GFR was calculated using the Nankivell formula. A normal GFR is \>90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poorer kidney function. A GFR \<15 is consistent with kidney failure.

    Time frame: 6 and 12 months

  2. Serum Creatinine

    Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 mg/dL for females and 0.6 to 1.2 mg/dL for males; however, the normal values are age-dependent as elderly patients typically have smaller muscle mass.

    Time frame: Baseline, 6 and 12 months

  3. Patient and Graft Survival

    Patient survival defined as patients living with or without a functioning graft. Graft survival defined as those patients who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.

    Time frame: 12 months

  4. Number of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 12 After Transplantation

    The diagnosis of acute rejection required a kidney biopsy. Biopsies were assessed using the Banff criteria, standardized diagnostic categories based on histological assessments (e.g., cell types and distributions).

    Time frame: 12 months after transplantation

07

Results

Posted Jan 7, 2010

Participant flow

Patients were recruited in Korea from March 2007 to November 2007.

Participant flow — Overall Study
MilestoneSirolimus (SRL)
Started79
Completed59
Not completed20
Withdrew: Adverse event1
Withdrew: Serious adverse event14
Withdrew: Withdrawal by subject2
Withdrew: Protocol violation3

Outcome measures

PrimaryNumber of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 6 After Transplantation.

The diagnosis of acute rejection required a kidney biopsy. Biopsies were assessed using the Banff criteria, standardized diagnostic categories based on histological assessments (e.g., cell types and distributions).

Time frame:
6 months after transplantation
Reported as:
Number · patients
Number of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 6 After Transplantation.
patientsSirolimus (SRL)
Number of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 6 After Transplantation.12
SecondaryGlomerular Filtration Rate (GFR) (Nankivell Method)

GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. For this study, GFR was calculated using the Nankivell formula. A normal GFR is \>90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poorer kidney function. A GFR \<15 is consistent with kidney failure.

Time frame:
6 and 12 months
Reported as:
Mean · mL/min
Glomerular Filtration Rate (GFR) (Nankivell Method)
mL/minSirolimus (SRL)
6 months67.36 ± 15.25
12 months71.92 ± 18.82
SecondarySerum Creatinine

Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 mg/dL for females and 0.6 to 1.2 mg/dL for males; however, the normal values are age-dependent as elderly patients typically have smaller muscle mass.

Time frame:
Baseline, 6 and 12 months
Reported as:
Mean · mg/dl
Serum Creatinine
mg/dlSirolimus (SRL)
Baseline9.42 ± 3.64
6 months1.30 ± 0.36
12 months1.25 ± 0.43
SecondaryPatient and Graft Survival

Patient survival defined as patients living with or without a functioning graft. Graft survival defined as those patients who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.

Time frame:
12 months
Reported as:
Number · patients
Patient and Graft Survival
patientsSirolimus (SRL)
Patient survival 6 months77
Patient survival 12 months76
Graft survival 6 months77
Graft survival 12 months76
SecondaryNumber of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 12 After Transplantation

The diagnosis of acute rejection required a kidney biopsy. Biopsies were assessed using the Banff criteria, standardized diagnostic categories based on histological assessments (e.g., cell types and distributions).

Time frame:
12 months after transplantation
Reported as:
Number · patients
Number of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 12 After Transplantation
patientsSirolimus (SRL)
Number of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 12 After Transplantation15

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sirolimus (SRL)—39/79 (49.4%)79/79 (100%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventSirolimus (SRL)
Blood creatinine increasedInvestigations10/79
Herpes zosterInfections and infestations6/79
LymphoceleVascular disorders6/79
PneumoniaInfections and infestations5/79
DiarrhoeaGastrointestinal disorders3/79
DeathGeneral disorders3/79
GastroenteritisInfections and infestations2/79
Urinary tract infectionInfections and infestations2/79
PyrexiaGeneral disorders2/79
HyperglycaemiaMetabolism and nutrition disorders2/79
Most frequent other events
Showing 10 of 188
Most frequent other events
EventSirolimus (SRL)
ConstipationGastrointestinal disorders31/79
Blood cholesterol increasedInvestigations29/79
Upper respiratory tract infectionInfections and infestations26/79
Procedural painInjury, poisoning and procedural complications24/79
DiarrhoeaGastrointestinal disorders21/79
HypercholesterolaemiaMetabolism and nutrition disorders19/79
AnaemiaBlood and lymphatic system disorders19/79
AcneSkin and subcutaneous tissue disorders18/79
Alanine aminotransferase increasedInvestigations17/79
NauseaGastrointestinal disorders16/79

Baseline characteristics

Age Continuous
Age Continuous(years)Sirolimus (SRL)
Mean40.16 ± 12.69
Sex: Female, Male
Sex: Female, Male(Participants)Sirolimus (SRL)
Female47
Male32
08

Study locations

9 sites
  • Deagu, 700-712, Korea, Republic of
  • Deagu, 700-721, Korea, Republic of
  • Pusan, 614-735, Korea, Republic of
  • Seoul, 110-744, Korea, Republic of
  • Seoul, 120-752, Korea, Republic of
  • Seoul, 135-710, Korea, Republic of
  • Seoul, 137-701, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
  • Suwon, 443-721, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2007
First posted
May 25, 2007
Start
Mar 2007
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Jan 7, 2010
Last update
Apr 28, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00478608
First posted
May 25, 2007
Start date
Mar 2007
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Jan 7, 2010
Last update
Apr 28, 2010

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion